NCT01014936View on ClinicalTrials.gov

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Interventions
DRUG

MSC2156119J

Trial Locations (1)

Unknown

M.D. Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

EMD Serono
All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

EMD Serono

INDUSTRY

NCT01014936 - First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter